Fredun Pharmaceuticals Management Guidance Tracker

Legacy business (exports, institutional, third-party) expected to grow 12-18% annually driven by 1,300-1,400 product registrations.

Dermatics, pet care, and nutritionals expected to grow 20-25% annually; 51% of revenue by FY29-30.

Mobility business expected to achieve ₹100 crore run-rate within 2-2.5 calendar years, and ₹250-300 crore in 5-7 years.

Operating leverage from high-margin new-age brands will drive profit growth over next 6-7 quarters.

Management targets PAT margin of 10-12% within the next few years as new-age businesses scale and demographics saturate.

Current funds and internal cash flows sufficient; no equity raise planned in near term.

Management expects overall revenue growth of 25-30% in FY27, driven by new-age businesses and steady vintage growth.

Pet care e-commerce platform Vagger.in to soft-launch in mid-June and full launch in first week of July 2026.